Chardan lowered the firm’s price target on Achilles Therapeutics to $6 from $11 and keeps a Buy rating on the shares. The analyst said that Achilles’ monotherapy program is yielding scientifically interesting translational insights, but competition is “mounting.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACHL:
- Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights
- Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
- Achilles Therapeutics Plc (ACHL) Q4 Earnings Cheat Sheet
- Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference
